Houseboy,
Here ya go:
Serial blood-based analysis of AR-V7 in men with advanced prostate cancerAs you can see, it was a very small study, and it is only suggestive. But what is there to lose by re-challenging with Xtandi and/or Zytiga now?
Another very interesting prospect is the restoration of Xtandi sensitivity using a PD-L1 blocker (like Keytruda). You'd only be able to get that in a clinical trial, however.
- Allen